Oramed Issues Annual Message to Shareholders

– Oral insulin program continues to advance with topline efficacy data expected in H2 2022 – Significant value creation opportunities through oral COVID-19 vaccine program and partnerships – Well positioned to capitalize on opportunities with strong cash balance of ~$174 million as of December 3,

Join our mailing list

Skip to content